Merck & Co., Inc. (NYSE:MRK) Stock Gets Price Target Increase from JPMorgan Chase & Co.

Merck & Co., Inc. (NYSE:MRK) had its price objective raised by equities research analysts at JPMorgan Chase & Co. from $165.00 to $175.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 16.86% from the stock’s previous close.

A number of other analysts have also recently weighed in on MRK. Guggenheim increased their price target on Merck & Co., Inc. from $170.00 to $171.00 and gave the stock a “buy” rating in a research report on Friday. Wolfe Research raised their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 25th. Citigroup boosted their price objective on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. Berenberg Bank increased their target price on shares of Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a report on Friday, September 11th. Finally, Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Seventeen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $153.36.

Merck & Co., Inc. Trading Up 2.3%

Shares of MRK stock traded up $3.42 during trading hours on Friday, hitting $149.75. 12,341,136 shares of the company were exchanged, compared to its average volume of 10,677,021. The firm has a market cap of $369.46 billion, a P/E ratio of 119.80, a P/E/G ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The company has a 50 day simple moving average of $146.89 and a two-hundred day simple moving average of $126.49. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The firm had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.58 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 2.64 EPS for the current year.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Several hedge funds have recently made changes to their positions in MRK. MFG Investments LLC bought a new position in shares of Merck & Co., Inc. in the third quarter worth approximately $364,000. Provenance Wealth Advisors LLC increased its position in shares of Merck & Co., Inc. by 997.3% during the third quarter. Provenance Wealth Advisors LLC now owns 16,811 shares of the company’s stock worth $2,443,000 after purchasing an additional 15,279 shares in the last quarter. Hughes Financial Services LLC grew its stake in shares of Merck & Co., Inc. by 10.7% in the third quarter. Hughes Financial Services LLC now owns 1,286 shares of the company’s stock valued at $188,000 after buying an additional 124 shares in the last quarter. Integras Partners LLC purchased a new position in Merck & Co., Inc. during the 3rd quarter worth approximately $223,000. Finally, Lyell Wealth Management LP raised its position in shares of Merck & Co., Inc. by 4.4% in the third quarter. Lyell Wealth Management LP now owns 11,294 shares of the company’s stock valued at $1,641,000 after buying an additional 478 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.